Volume 13, Issue 6 (November 2011) 13, 895–897; 10.1038/aja.2011.44
Preliminary study of letrozole use for improving spermatogenesis in non-obstructive azoospermia patients with normal serum FSH
Giorgio Cavallini1, Giovanni Beretta2 and Giulio Biagiotti3
1 Andros-Italia, Outpatient Clinic of Ferrara, Via Mascheraio 46, Ferrara 44121, Italy 2 Centro Italiano Fertilità e Sessualità, Via della Fortezza 6, Firenze 50129, Italy 3 Andros Italia, Sede di Perugia, Via Martiri dei Lager 58, Perugia 06128, Italy
Correspondence: Dr G Cavallini, (giorgiocavallini@libero.it)
Received 25 December 2010; Revised 23 February 2011; Accepted 11 April 2011; Published online 27 June 2011
Abstract |
We investigated whether letrozole (2.5 mg day(-1)) improves sperm count in non-obstructive azoospermia (NOA) patients. Four men were included in this study, and they had folliculo-stimulating hormone and other hormone levels within the normal range and no varicoceles or chromosomal aberrations. These four patients were administered letrozole for 3 months. Sperm count, testicular volume, gonadotropin, testosterone (T) and estradiol (E2) blood levels were assessed before, during and 1 week after the suspension of treatment. All patients showed spermatozoa in their ejaculate, increased gonadotropin and T levels and lower E2 levels (P<0.05 in all cases), when letrozole was administered. This suggests that letrozole treatment might improve sperm count in an NOA sub-population; however, more studies, including the proper controls, are needed to confirm its efficacy.
Keywords: letrozole; medical treatment; non-obstructive azoospermia; spermatogenesis
PDF |
PDF |
中文摘要 |
|
|
Browse: 3618 |
|